Vaccinex Price To Sales vs. Shares Owned By Institutions

VCNX Stock  USD 3.62  0.02  0.56%   
Based on the key profitability measurements obtained from Vaccinex's financial statements, Vaccinex may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Vaccinex's ability to earn profits and add value for shareholders.

Vaccinex Price To Sales Ratio

7.19

Price To Sales Ratio is likely to drop to 7.19 in 2024. Days Sales Outstanding is likely to drop to 450.71 in 2024. At this time, Vaccinex's Change To Netincome is fairly stable compared to the past year. Income Quality is likely to rise to 1.14 in 2024, whereas Net Interest Income is likely to drop (1.1 K) in 2024.
For Vaccinex profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vaccinex to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vaccinex utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vaccinex's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vaccinex over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaccinex. If investors know Vaccinex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaccinex listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
7.42
Revenue Per Share
0.318
Quarterly Revenue Growth
(0.81)
Return On Assets
(4.96)
Return On Equity
(7.59)
The market value of Vaccinex is measured differently than its book value, which is the value of Vaccinex that is recorded on the company's balance sheet. Investors also form their own opinion of Vaccinex's value that differs from its market value or its book value, called intrinsic value, which is Vaccinex's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaccinex's market value can be influenced by many factors that don't directly affect Vaccinex's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaccinex's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaccinex is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaccinex's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Vaccinex Shares Owned By Institutions vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Vaccinex's current stock value. Our valuation model uses many indicators to compare Vaccinex value to that of its competitors to determine the firm's financial worth.
Vaccinex is rated fourth in price to sales category among its peers. It is rated fourth in shares owned by institutions category among its peers producing about  1.80  of Shares Owned By Institutions per Price To Sales. At this time, Vaccinex's Price To Sales Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vaccinex's earnings, one of the primary drivers of an investment's value.

Vaccinex Shares Owned By Institutions vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Vaccinex

P/S

 = 

MV Per Share

Revenue Per Share

 = 
27.22 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Vaccinex

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
49.12 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Vaccinex Shares Owned By Institutions Comparison

Vaccinex is currently under evaluation in shares owned by institutions category among its peers.

Vaccinex Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Vaccinex, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vaccinex will eventually generate negative long term returns. The profitability progress is the general direction of Vaccinex's change in net profit over the period of time. It can combine multiple indicators of Vaccinex, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income(1,000.00)(1,050)
Interest Income20.7 K19.7 K
Operating Income-22.9 M-24 M
Net Loss-22 M-23.1 M
Income Before Tax-20.3 M-21.3 M
Total Other Income Expense Net2.6 M1.4 M
Net Loss-20.1 M-21.1 M
Net Loss-20.3 M-21.3 M
Income Tax Expense-48.9 K-46.5 K
Change To Netincome626.8 K658.1 K
Net Loss(43.68)(45.86)
Income Quality 0.85  1.14 
Net Income Per E B T 0.90  0.81 

Vaccinex Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Vaccinex. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vaccinex position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vaccinex's important profitability drivers and their relationship over time.

Use Vaccinex in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaccinex position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaccinex will appreciate offsetting losses from the drop in the long position's value.

Vaccinex Pair Trading

Vaccinex Pair Trading Analysis

The ability to find closely correlated positions to Vaccinex could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaccinex when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaccinex - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaccinex to buy it.
The correlation of Vaccinex is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaccinex moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaccinex moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vaccinex can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Vaccinex position

In addition to having Vaccinex in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Value Funds Thematic Idea Now

Small Value Funds
Small Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Vaccinex Stock Analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.